Abbott Laboratories Articles
Positive Ph III results for AbbVie's Humira in pediatric Crohn's disease; five leukemia studies suspended
17 February 2013
Abbott Labs 4th-qtr net income plunges
23 January 2013
Patient trust in drugmakers declining, new report shows
14 January 2013
Global rheumatology market controlled by Enbrel, Humira and Remicade
24 December 2012
Abbott board prepares way for AbbVie split off
29 November 2012
Biosimilars threaten to burst Humira's blockbuster bubble
29 November 2012
EU Commission approves Bayer's Eylea for wet AMD and Abbott's Humira for pediatric Crohn's
28 November 2012
Abbott launches Sucampo's Amitiza in Japan
27 November 2012
Abbott presents new Humira data at ACR
12 November 2012
AET BioTech and BioXpress to co-develop biosimilar Humira
2 November 2012
Seattle Genetics and Abbott expand ADC collaboration
24 October 2012
Good news from CHMP for Astellas, Savient, Bayer and Abbott, but not for Lundbeck and Merz
22 October 2012
FDA extends PDUFA date for Biogen Idec's MS drug BG-12; Abbott and Reata's bardoxolone stalled
19 October 2012
Abbott Laboratories to acquire Russian firm Petrovax Farm?
15 October 2012
Abbott's Humira gets FDA backing for new use
30 September 2012
Top drugmakers set up non-profit TransCelerate to speed pharma R&D
20 September 2012
Astellas to use Abbott's CMV assay for vaccine trial
6 September 2012
Abbott's Humira cleared for Crohn's disease in EU
31 August 2012
Abbott's Humira gains FDA panel backing for wider use
29 August 2012
Gap in patent filings for biological and small-molecule drugs widening, says Withers & Rogers
20 March 2012
Watson confirms Abbott Niaspan patent challenge
19 March 2012
Abbott unit snaps up LIMS distributors
4 March 2012
EMA advisory backs Humira for UC and expanded use of Byetta
20 February 2012
Abbott on track to split; posts higher earnings
26 January 2012
Emergent considers options as Abbott ends drug R&D collaboration
30 December 2011
Abbott in further deal with Reata
12 December 2011
US gastroenterologists see significant growth for Abbott/Eisai’s Humira in ulcerative colitis once indication is approved
29 November 2011
Public health groups launch global campaign against Abbott Labs’ monopoly on critical AIDS medicine
11 November 2011
Litigation hits Abbott Lab’s 3rd-qtr, but shares leap as firm says it will split in two
20 October 2011
Abbott and Eisai launch of PDER drug Lipacreon in Japan
31 August 2011
Abbott Labs 2nd-qtr profit rocket 50%, with sales boosted by Humira and emerging markets
21 July 2011
More Japanese drug OKs: GSK’s Rotarix and Lamictal; Takeda’s Liovel and new use for Eisai/Abbott’s Humira
4 July 2011
Abbott debuts pediatric Humira in UK; gets US FDA appro for first infant-specific dosage for Creon
15 June 2011
Highlights from Digestive Disease Week
11 May 2011
Lupin in deal with Abbott and Fournier for Antara; Sun Pharma to sell Merck & Co diabetes drugs
27 April 2011
Abbott Labs 1st-qtr 2011 sales jump 17% but profits down 14% on acquisitions and restructuring
21 April 2011
GlaxoSmithKline gains EU appro for epilepsy drug Trobalt; Lovaza patent accord; gets $3.5M from Abbott
31 March 2011
Depomed regains rights to Gralise from Abbott; licenses Acuform to Boehringer Ingelheim
18 March 2011
Abbott prevails as US Court of Appeals overturns $1.8 billion patent verdict for J&J unit
24 February 2011
US FDA clears use of Novartis’ Menveo for over two-year-olds; Depomed leaps on approval of shingles drug Gralise
31 January 2011
Abbott Labs meets 4th-qtr 2010 expectations, despite 6% fall in net due to acquisitions
27 January 2011
USA and China plan increasing private-public collaboration in the health care sector
25 January 2011
Depomed seeks resolution of dispute with Abbott Labs over neuralgia drug candidate DM-1796
20 January 2011
Abbott Labs pulls its MMA and BLA for psoriasis drug Ozespa
18 January 2011
As patent cliffs and law suits rule US generic drug industry, research-based majors look to deals and diversification
4 January 2011
Three drugmakers - Abbott, Roxane and Braun - to pay $421 million to settle false claims cases, says US Justice Dept
8 December 2010
Abbott Labs files suit against Impax over Simcor patent challenge; Ranbaxy debuts generic Aricept in USA
29 November 2010
Abbott/Eisai's Humira emerges as market leader in psoriatic arthritis, garnering sales of over $500 million in 2009
5 November 2010
New label warnings on use of Roche’s HIV drug Invirase together with Abbott’s Norvir imposed by US FDA; EMEA calls for lower starting dose
22 October 2010
Solvay costs and Meridia withdrawal take heavy toll on Abbott Labs 3rd-qtr 2010 results
21 October 2010
Abbott enters $450 million deal with Reata Pharma to gain rights to methyl for kidney disease outside USA
24 September 2010
Abbott Labs plans cost-cutting, 3,000 job losses as a result of Solvay integration
22 September 2010
US FDA advisory panel split on keeping Abbott’s obesity drug Meridia on the market
16 September 2010
Abbott Labs gives up on vaccines unit sale, as no adequate bidders in sight; heart risks reported with obesity drug Meridia
6 September 2010
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
